Simulations Plus, Inc. (SLP)
Oxford Ledge is still expanding full research coverage of SLP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Simulations Plus provides drug development software and consulting services across discovery, clinical trials, and commercialization.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-07-09
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-07-09
- 8-K Entry into material agreement; Departure/election of directors or officers; Financial statements and exhibits 2026-06-17
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-16
- 10-Q Quarterly financial report (unaudited) 2026-04-10
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for SLP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SLP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.